您当前的位置：
首页 >
文章列表页 >
Evolution and associated factors of out-licensing deals by Chinese biopharmaceutical companies
更新时间：2026-07-28

    • Evolution and associated factors of out-licensing deals by Chinese biopharmaceutical companies

    • ZHONGGUO YAOFANG   Vol. 37, Issue 14, Pages: 1805-1812(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.14.02    

      CLC： R95

    • Received：18 March 2026，

      Revised：2026-07-13，

      Accepted：14 July 2026，

      Online First：24 July 2026，

      Published：30 July 2026

    移动端阅览

  • YU Xiaoyi,PEI Zhongfei,SUN Yinuo,et al.Evolution and associated factors of out-licensing deals by Chinese biopharmaceutical companies[J].ZHONGGUO YAOFANG,2026,37(14):1805-1812. DOI： 10.6039/j.issn.1001-0408.2026.14.02.

  •  
  •  

0

Views

4

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Study on the mechanism of Euphorbia hirta L.-derived exosome-like nanovesicles regulating Nrf2/HO-1/NQO1 pathway to improve acetaminophen-induced liver injury
Study on the influencing factors of venetoclax trough concentration and its association with efficacy in patients with acute myeloid leukemia
Meta-analysis of the effects of different doses of vitamin D supplementation on maternal and infant outcomes in vitamin D-deficient pregnant women
Mechanism of Qingre antai decoction in improving pregnancy outcomes of threatened abortion rats with blood heat syndrome based on JAK2/STAT3 and PI3K/AKT dual signaling pathways
Signal mining for bleeding risk associated with the concomitant use of direct oral anticoagulants and triazole antifungals

Related Author

No data

Related Institution

No data
0